GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPHW) » Definitions » EV-to-EBITDA

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) EV-to-EBITDA : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Reviva Pharmaceuticals Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Reviva Pharmaceuticals Holdings's enterprise value is $0.00 Mil. Reviva Pharmaceuticals Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-40.33 Mil. Therefore, Reviva Pharmaceuticals Holdings's EV-to-EBITDA for today is 0.00.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's EV-to-EBITDA or its related term are showing as below:

RVPHW' s EV-to-EBITDA Range Over the Past 10 Years
Min: -40.34   Med: 0   Max: 0
Current: -0.78

RVPHW's EV-to-EBITDA is ranked worse than
100% of 450 companies
in the Biotechnology industry
Industry Median: 9.385 vs RVPHW: -0.78

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-08), Reviva Pharmaceuticals Holdings's stock price is $0.23. Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.000. Therefore, Reviva Pharmaceuticals Holdings's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Reviva Pharmaceuticals Holdings EV-to-EBITDA Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings EV-to-EBITDA Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
- -30.90 -1.41 -2.42 -3.05

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.71 -3.50 -2.53 -3.05 -2.33

Competitive Comparison of Reviva Pharmaceuticals Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reviva Pharmaceuticals Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's EV-to-EBITDA falls into.



Reviva Pharmaceuticals Holdings EV-to-EBITDA Calculation

Reviva Pharmaceuticals Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=0.000/-40.329
=0.00

Reviva Pharmaceuticals Holdings's current Enterprise Value is $0.00 Mil.
Reviva Pharmaceuticals Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reviva Pharmaceuticals Holdings  (NAS:RVPHW) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Reviva Pharmaceuticals Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.23/0.000
=N/A

Reviva Pharmaceuticals Holdings's share price for today is $0.23.
Reviva Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Reviva Pharmaceuticals Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Headlines

From GuruFocus